Taro stake buyout to help operate its dermatology biz profitably amid enhanced competition: Sun Pharma

Sun Pharma is looking to fully acquire its Israel-based unit Taro Pharmaceutical Industries in order to integrate the dermatology business with itself and keep it profitable amid increasing competition in the segment, according to Managing Director Dilip Shanghvi. The Mumbai-based drug major has proposed to fully acquire Taro through a reverse triangular merger.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9s7hy1N
via IFTTT